GNPDA2

Across TCGA pan-cancer cohorts, GNPDA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GNPDA2 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher GNPDA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated GNPDA2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

CCRCC, PDAC, and LSCC are the cancer types where GNPDA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Quartile	III,IV	0.824	0.288	.005	46	view →
PDAC	DFS	Tertile	All	0.895	0.660	.001	40	view →
LSCC	OS	Quartile	II,III,IV	0.584	1.000	.009	21	view →
HNSC	OS	Tertile	II,III,IV	0.919	1.000	.007	8	view →
LUAD	DFS	Quartile	All	0.749	0.426	.029	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GNPDA2–CCRCC (OS)

Open the CCRCC breakdown →